For those of you who took an interest in the UK Seroxat litigation, a full judgement has been posted online here.
The judgement stipulates, "...the Claimants should pay the Defendant's costs of this litigation; those costs are paid on an indemnity basis from 21 June 2018 and there should be a payment on account of costs in the sum of £4.5 million."
The judgement stipulates, "...the Claimants should pay the Defendant's costs of this litigation; those costs are paid on an indemnity basis from 21 June 2018 and there should be a payment on account of costs in the sum of £4.5 million."
With one case over, newer ones may be looming with regards to Seroxat causing birth defects, unless, of course, cases like these can't go to trial due to the Statute of Limitations coming into play.
"...the researchers noted that, compared to control groups, paroxetine-exposed mini-brains developed with up to 75% fewer oligodendrocytes, the support cells that are crucial for the proper "wiring" of the brain."
"...the researchers noted that, compared to control groups, paroxetine-exposed mini-brains developed with up to 75% fewer oligodendrocytes, the support cells that are crucial for the proper "wiring" of the brain."
"The scientists, who published their findings in February in Frontiers of Cellular Neuroscience, used the mini-brains to determine that the antidepressant paroxetine, commonly called Paxil or Seroxat, suppresses the growth of synapses, which are the connection points between neurons, and leads to significant decreases in an important support-cell population. Paroxetine, which can cross the placenta in pregnant women, currently comes with a warning against use in early pregnancy, largely due to a known risk of heart and lung defects. Some epidemiological studies also have suggested that paroxetine raises the risk of autism."
Full story here.
Bob Fiddaman
No comments: